Trade Journal

Committee approved OPEN at 2.0% weight — price-below-value (MEDIUM confidence)

Committee approved OPEN at 2.2% weight — price-below-value (MEDIUM confidence)

Committee approved OPEN at 2.4% weight — price-below-value (MEDIUM confidence)

Committee approved OPEN at 2.1% weight — price-below-value (MEDIUM confidence)

Committee approved OPEN at 2.0% weight — price-below-value (MEDIUM confidence)

Committee approved OPEN at 2.0% minimum weight (54 shares at $36.60). Contrarian consumer staples thesis where market prices in strategy failure while 5 of 7 ensemble markets lean positive. Kelly formula produced 1.69%, below 2% minimum, so floor weight applied. Consumer staples adds a new sector to the portfolio for diversification. Minimum sizing limits downside to immaterial NAV impact. Key catalyst: FY2027 guidance release expected June 2026.

Committee approved OPEN at 2.0% minimum weight (35 shares at $57.30). Auto supplier with 200bps cumulative margin expansion, clean accounting, and strong model agreement (0.93-0.98) across 7 lenses. Quarter-Kelly computed 2.05%, rounded to 2.0% floor. Position provides Auto Parts/Industrials diversification. Key risk: 45% tariff probability as thesis-invalidating scenario. Monitoring triggers: Q1 2026 earnings (mid-May), tariff escalation above 60%, camera recall resolution below 50%, -15% loss stop, 60-day staleness (2026-05-21).

Clear asymmetric risk profile: bear-case scenarios carry low probabilities (4-15%) with high model agreement while growth metrics show strong momentum (70-74%). Exceptionally high model agreement (0.92-0.98), CEO insider purchases. Auto-approve conditions met.

Portfolio transformation with 4 of 7 markets leaning constructive and consistently high model agreement (0.88-0.93). Contained tail risk (PFAS at 17%), near-term earnings catalyst (Q1 2026). Industrials sector diversification to Technology-heavy portfolio.

80/20 transformation producing real results (37% EBITDA growth, share gains). Insider buying at $37-39 provides alignment. Containerboard pricing optionality creates asymmetric upside. ~5% dividend yield provides current income. Committee sized at Kelly output (2.1%) due to DA concerns.

FCF generation at $4.44B with 93% conversion indicates underlying business economics intact despite 75% stock decline. 22% goodwill impairment probability supports pricing phenomenon over permanent asset destruction. Mandatory post-Investor Day review (May 14).

Near-universal rejection of catastrophic gold decline (7%, 0.97 agreement) with $1,350/oz AISC providing margin above breakeven. $380M net cash and $330M FCF mean growth is self-funded. Portfolio's Basic Materials diversification.

Ensemble's highest-conviction signal: 96% model agreement gold unlikely to fall below $3,500/oz. 0.22x leverage ratio and $530M cash provide balance sheet floor. Mining/metals diversification not available from existing holdings.

Structural-vs-cyclical disconnect: three lenses validated durable margin improvement (300bps since 2019), balance sheet stability (82% below 3.5x leverage), and operational execution tracking well (82% SAP). Cyclical trough valuation for structural improvement story.

Compelling valuation at ~5x guided EBITDA for world's largest independent driveline supplier. Insider purchases at $5.20 reinforce conviction. Highest tail risk discount (-0.30) reflects leverage and integration risk, sized conservatively at 2.4%.

Franchise durability signal at odds with market pricing: 80% renewal rate probability above 91% with 0.96 agreement, combined with 30% FCF yield on actual cash generation. Value trap risk acknowledged but sized conservatively at 2.1%.

Asymmetric risk-reward: low-probability tail risks (Mali at 12%) combined with near-certain deleveraging (prepay at 90%) and coin-flip growth catalysts (Fekola permit at 50%). Commodity and geographic diversification to Technology/Financial-heavy portfolio.

Structural transformation story with exceptionally clean fundamentals — CEO with $550M+ personal stake, highest utilization in steel industry. Aluminum diversification provides optionality. Materials/Industrials diversification to portfolio with zero cyclical industrial exposure.

Record $3B+ earnings, 22% crash on Iran fuel fears appears overreactive. Mandatory review within 24h of Q1 earnings (March 25). Close if miss + guidance cut.

DOMINANT regional jet monopoly with $31.6B backlog, net cash balance sheet, tariff exemption worth $80M/yr. Quarter-Kelly sizing at 2.27%.

946M MAU at 1.2x revenue with $437M FCF. Market embeds excessive pessimism. eCPM structural risk and dual-class governance are real but sized conservatively.

Opening minimum-threshold position in BAH based on price-below-value classification (MEDIUM confidence). Stock at 13.4x achievable FY2026 EPS with $825-900M FCF, $38B+ backlog, and cleared workforce moat. Quarter-Kelly sizing at 2.2% reflects heavy tail risk discount from DOGE policy uncertainty and funded backlog decline. Devil's Advocate raised mixed assessment on correlated policy risk, adequately mitigated by minimum position size.

Merger arbitrage: BlackRock-led take-private at $15/share with 70% deal completion probability. 6.4% spread to deal value. First utilities/renewables exposure adds diversification. Quarter-Kelly sizing at 2.85%.

Crisis narrative dramatically overstated vs record $56B fundraising, $300B+ AUM, 8bps loss rates. Software nonaccruals 86% likely to stay <1%, SEC enforcement only 10% probable. Near-term BDC flow headwinds real but priced into conservative sizing.

Committee approved opening position at quarter-Kelly 2.24% weight. Thesis classifies RUN as price-below-value at MEDIUM confidence. Prediction ensemble assigns low probabilities (13-22%) to all three thesis-breaking tail risks with high model agreement (0.90-0.93). Position sized conservatively after -0.30 tail risk discount for three escalate markets.

Committee approved opening PINS at minimum quarter-Kelly weight (2.1%). Thesis: price-below-value with MEDIUM confidence — 40% decline to 6-year lows appears disproportionate to operational fundamentals. Ensemble assigns 11-27% probability to all bear-case scenarios. Kill shot: Q1 earnings showing revenue <10% AND ARPU compression.

Committee approved OPEN with modification at 2.0% weight (8 shares at $248.56). Q1 FY2026 revenue of $6.40B decisively triggered the prior committee's pre-approved beat scenario ($6.30B threshold). Risk Manager's quarter-Kelly computation (1.51%, bumped to 2.0% floor) is the binding constraint. Analyst's proposed 2.5% override denied — three independent inputs converged at 2.0%. CEO transition is a genuinely new risk that the framework cannot yet quantify, but 2.0% sizing limits max tail-risk loss to 0.5-0.6% NAV. Conditions: no ADD until CEO successor announced with strategic continuity, FTC case resolved, or Q2 margin holds above 44.0%.

Committee approved OPEN with modification. MEDIUM confidence price-below-value thesis with 8 active markets and 0.91-0.97 model agreement. Quarter-Kelly sizing at 2.1% — formula narrowly clears 2.0% minimum. Analyst's 3.0% override denied; Risk Manager's formula output accepted. Three conditions: no ADD until primary catalyst resolves, re-evaluate if Q1 revenue < 17% CC, run Black Swan Beacon before scaling.

Committee approved ADD after Q4 FY2026 earnings update. Thesis confidence upgraded MEDIUM to MEDIUM-HIGH — two markets resolved YES (revenue beat Brier 0.3364, margin 20% Brier 0.1444), all bear case probabilities declined. Price dropped 25% from prior assessment ($32.38 to $24.33) while operational fundamentals improved. Quarter-Kelly sized to 3.5% — $400M buyback provides new price support mechanism.

Committee approved OPEN at 2.16%. MEDIUM confidence price-below-value with 8 active markets (0.89-0.97 agreement). Accounting scandal overhang creates narrative-reality gap at 19x forward PE while delivering 20%+ EPS growth.

Committee approved OPEN at 2.05%. MEDIUM confidence price-below-value with 6 active markets. Stock trades near cash value ($8.1B) with pipeline catalysts (74% intl flu approval, 37% oncology Phase 3). New Healthcare sector provides portfolio diversification.

Committee approved OPEN at 2.3%. MEDIUM confidence price-below-value with 7 active markets. At 8x trailing earnings and 6x FCF, stock prices compounding catastrophe that ensemble rejects at 3-11% probability with near-unanimous agreement.

Committee approved OPEN at 2.02%. MEDIUM confidence price-below-value with 8 active markets. At 17x forward FCF with first GAAP profit and $945M FCF, price embeds conservative 8-9% guidance rather than documented guide-low-raise-high pattern.

Committee approved OPEN at 3.16%. MEDIUM confidence price-below-value with 9 active markets. Minor magnitude produces higher raw Kelly (0.126) due to lower odds denominator. Quarter-Kelly at 3.16% reflects strong payment network fundamentals despite regulatory overhang (CCCA 36%, DOJ 28%).

Committee approved OPEN at 2.3%. MEDIUM confidence price-below-value thesis with 7 active markets and 0.88-0.95 model agreement. Quarter-Kelly sizing at 2.3% — near minimum threshold — reflects genuine uncertainty around Duo Agent fulcrum and DBNRR trajectory.

Committee approved OPEN. MEDIUM confidence price-below-value thesis with 8 active markets. Quarter-Kelly sizing at 3.6% driven by minor magnitude odds (low asymmetry) producing higher raw Kelly. Fractional shares required due to high share price.

Committee approved OPEN. MEDIUM confidence price-below-value thesis with 8 active markets. Quarter-Kelly sizing at 2.1% reflects moderate edge with AI efficiency breakthrough as key risk.

Committee approved OPEN. HIGH confidence price-below-value thesis with 9 active markets. Quarter-Kelly sizing at 3.0% reflects strong edge. Immediate re-evaluation after Abel shareholder letter (~Feb 28).

Committee approved OPEN. HIGH confidence price-below-value thesis with 8 active markets and 0.88-0.99 model agreement. Quarter-Kelly sizing at 3.5% reflects strong edge with adequate tail risk buffer.